Treatment of metastatic HER2 positive breast cancer in young patient with very advanced disease – case report
04/2019
MUDr. Markéta Protivánková1; MUDr. Dagmar Brančíková, Ph.D.1; MUDr. Jiří Vašina2,3
1 Interní hematologická a onkologická klinika LF MU a FN Brno
2 Oddělení nukleární medicíny a PET centrum, Masarykův onkologický ústav, Brno
3 Nuclear cardiology ICRC, LF MU a FN u sv. Anny, Brno
SUMMARY
Although the percentage of patients diagnosed in the early stage of the disease is increasing after the introduction of breast cancer screening, a large group of patients still have metastatic breast cancer. Advanced HER2 positive breast cancer has been therapeutically difficult to treat with adverse prognosis until the introduction of targeted anti-HER2 therapy, and its therapy has been complicated by a number of possible side effects and considerable toxicity. Our case report describes a case of a 42-year-old patient who had HER2 positive breast cancer diagnosed at a very advanced stage of the disease. After the use of dual-block treatment with concomitant administration of trastuzumab and pertuzumab, a high-quality and long-term response of the disease was achieved in which the quality of life of the patient significantly increased. At the same time, this treatment was very well tolerated.
Key words
HER2 positive metastatic breast cancer, pertuzumab, trastuzumab
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...